Bleomycin exerts ambivalent antitumor immune effect by triggering both immunogenic cell death and proliferation of regulatory T cells.

Bleomycin exerts ambivalent antitumor immune effect by triggering both immunogenic cell death and proliferation of regulatory T cells.

Bleomycin (BLM) is an anticancer drug currently used for the treatment of testis cancer and Hodgkin lymphoma. This drug triggers cancer cell death via its capacity to generate radical oxygen species (ROS). However, the putative contribution of anticancer immune responses to the efficacy of BLM has n...

Full description

Saved in:
Bibliographic Details
Main Authors: Hélène Bugaut, Mélanie Bruchard, Hélène Berger, Valentin Derangère, Ludivine Odoul, Romain Euvrard, Sylvain Ladoire, Fanny Chalmin, Frédérique Végran, Cédric Rébé, Lionel Apetoh, François Ghiringhelli, Grégoire Mignot
Format: article
Language:EN
Published: Public Library of Science (PLoS) 2013
Subjects:
Medicine
R
Science
Q
Online Access:https://doaj.org/article/86b597f6dd8c41bea39c1cea84b3d20c
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items